quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:10:06·30d
SECFiling
LENZ Therapeutics Inc. logo

SEC Form 10-K filed by LENZ Therapeutics Inc.

LENZ· LENZ Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • LENZ
    LENZ Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Apr 14UpdatePiper Sandler$51.00
  • Mar 18UpdateTD Cowen$60.00
  • Sep 27UpdateRaymond James$37.00
  • Aug 12UpdateH.C. Wainwright$38.00
  • Apr 15UpdateWilliam Blair-
  • Apr 15UpdateLeerink Partners$32.00

Related

  • PR3d
    LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom
  • SEC15d
    SEC Form SCHEDULE 13G filed by LENZ Therapeutics Inc.
  • INSIDER24d
    SEC Form 4 filed by George Jeffrey P.
  • INSIDER24d
    SEC Form 4 filed by Schimmelpennink Evert B.
  • INSIDER24d
    SEC Form 4 filed by Chevallard Daniel R.
  • SEC30d
    SEC Form S-8 filed by LENZ Therapeutics Inc.
  • SEC30d
    LENZ Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • PR30d
    LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022